Friday, October 28, 2016

UNITY Biotechnology Raises $115M

San Francisco-based UNITY Biotechnology announced on Thursday that it has raised $116M in a Series B funding. The funding came from ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock, along with Bezos Expeditions, WuXi PharmaTech and Mayo Clinic Ventures. UNITY said it has named Keith Leonard as CEO as part of the funding; founder and previous CEO Nathaniel "Ned" David becomes President of the company. UNITY on treatments for diseases of aging, such as osteoarthritis, glaucoma, and atherosclerosis. More information »